Publications by authors named "P Schweitzer"
Permafrost thaw poses diverse risks to Arctic environments and livelihoods. Understanding the effects of permafrost thaw is vital for informed policymaking and adaptation efforts. Here, we present the consolidated findings of a risk analysis spanning four study regions: Longyearbyen (Svalbard, Norway), the Avannaata municipality (Greenland), the Beaufort Sea region and the Mackenzie River Delta (Canada) and the Bulunskiy District of the Sakha Republic (Russia).
View Article and Find Full Text PDFLarge-scale characterization of cocaine addiction-like behaviors reveals that escalation of intake, aversion-resistant responding, and breaking-points are highly correlated measures of the same construct.
Elife
November 2024
Article Synopsis
- Addiction involves increased drug use, compulsive seeking, and continued use despite harm, but why some users progress to this point isn't well understood, especially concerning sex differences.
- A study with over 500 diverse rats examining cocaine self-administration revealed that increased drug intake, persistence despite negative consequences, and reward-seeking were interconnected, while irritability during withdrawal stood apart.
- The research found that female rats showed more addiction-like behaviors and fewer resilient traits compared to males, indicating significant sex differences in addiction resilience.
BiOI is a promising material for use in photoelectrocatalytic water oxidation, renowned for its chemical inertness and safety in aqueous media. For device integration, BiOI must be fabricated into films. Considering future industrial applications, automated production is essential.
View Article and Find Full Text PDFObjective/background: Preference for extended-release, once-nightly sodium oxybate (ON-SXB, FT218) vs twice-nightly immediate-release (IR) oxybate was assessed in participants switching from IR oxybate to ON-SXB in an open-label/switch study, RESTORE (NCT04451668).
Patients/methods: Participants aged ≥16 years with narcolepsy who completed the phase 3 REST-ON trial, were oxybate-naive, or were on a stable IR oxybate dose (≥1 month) were eligible for RESTORE. For participants who switched from twice-nightly dosing to ON-SXB, initial doses were closest or equivalent to their previous nightly IR oxybate dose.